BackAgeX Therapeutics Overview

AgeX Therapeutics Net Income

Track AgeX Therapeutics's net income ($-24M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$8.93M
38.52% YoY

As of Jun 2026

Annual Net Income (TTM)

-$24.04M
791.1% YoY

Trailing 12 months ending Jun 2026

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

AgeX Therapeutics (AGE) FAQ

AgeX Therapeutics (AGE) currently reports a net income of $-24M as of June 2026. That compares with $-2.7M in the prior-year period — down 791.1% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore AgeX Therapeutics's net income history and peer comparisons.

AgeX Therapeutics's net income decreased from $-2.7M to $-24M — a 791.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AgeX Therapeutics's net income of $-24M is lower than the Healthcare sector average of $16B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

AgeX Therapeutics reported $-24M in net income as of June 2026. That compares with $-2.7M in the prior-year period — down 791.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-24M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for AgeX Therapeutics, and consider following AGE for alerts when major investors trade the stock.